Soligenix jumps on FDA's orphan drug tag for Behcet's disease therapy

Soligenix

18/08/2025 15:13

Updates

** Shares of therapy developer Soligenix SNGX.O rise 59.2% to $4.42

** Company says FDA has granted "orphan drug" tag for its Behcet's disease treatment, after the review of mid-stage study data

** Co is testing dusquetide, the active ingredient in SGX945, in patients with mild-to-moderate Behcet's disease

** Behcet's disease is a rare inflammatory disorder that can affect various parts of the body, most notably causing painful sores in the mouth and genitals, along with eye inflammation

** FDA grants orphan drug status to promote drug development for rare diseases affecting fewer than 200,000 people in the U.S.

** Including session moves, stock up 40.1% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))